Precision Medicine

Early trial data for tazbentetol shows promise in treating schizophrenia by rebuilding synapses, a potential paradigm shift in psychiatric medicine.

The successful launch of rosacea treatment Emrosi™ generated $14.7M, driving Journey Medical's revenue to $61.9M and signaling a major strategic win.

A new high-tech wellness center arrives in Boulder, offering cutting-edge services. But does the science support the high price of proactive health?

Aerin Medical's milestone highlights a major shift toward minimally invasive, in-office treatments for chronic nasal issues, moving beyond traditional surgery.

A new FDA-cleared device uses water vapor to ablate prostate tissue, showing high efficacy in trials while minimizing life-altering side effects.

SciTech's ST-001 overcomes a decades-old barrier for fenretinide, showing promising results for Cutaneous T-Cell Lymphoma patients in early trials.

Maze Therapeutics posts positive Phase 2 data for its genetic kidney disease drug, but a sharp stock drop reveals investor concerns in a competitive race.

Health Canada greenlights MeMed's rapid diagnostic tool, a major step in the nation's fight against deadly sepsis and growing antimicrobial resistance.

With $138M in total funding, Endogenex is advancing a novel device that aims to redefine type 2 diabetes treatment by healing the gut, not just managing symptoms.

Swedish biotech VERIGRAFT begins a pivotal trial for a personalized, lab-grown vein, offering hope for a true cure for millions with chronic venous insufficiency.

As oncologists warn of supplement risks, one company founded by a doctor and caregiver aims to provide a safer, transparent path for cancer survivors.

Experic and Flurry Powders form a strategic alliance to accelerate complex therapies by combining advanced particle engineering with GMP manufacturing.

With new financing from Avenue Capital, Turn Therapeutics bets big on its novel skin therapy, GX-03, to tackle multi-billion dollar dermatology markets.

A groundbreaking study proves a botanical compound enhances protein absorption, leading to measurable gains in muscle strength and mass, especially for older adults.

RA Capital's major investment extends Karyopharm's runway, but future funding is now directly tied to the outcome of its pivotal endometrial cancer trial.

With positive safety data for its novel UC drug, a €530M cash reserve, and a new commercial chief, Abivax is poised for a major market entry.

A new Phase 2 trial is testing an inhaled version of a key IPF drug, aiming to reduce severe side effects and transform treatment for the fatal lung disease.

New research reveals a startling link between common liver conditions and heart failure in older adults with atrial fibrillation, urging a new look at risk.

UK biotech Amphista to showcase its innovative Targeted Glue™ platform at AACR, revealing new data for AML, lung cancer, and mesothelioma therapies.

With a history of billion-dollar deals, Mark Altmeyer takes the helm at ReproNovo, aiming to commercialize its promising fertility and women's health pipeline.